Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Shares of Novavax Inc. NVAX rallied 6.11% to $6.34 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 4.35% to ...

Wall Street’s major averages ended the week slightly lower on Friday, losing gains for the week amid renewed optimism about ...

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Novavax (NASDAQ:NVAX) pivots back to profitability after delivering a $666.7 million revenue haul in Q1surpassing estimates by $322.8 millionand lifting its full-year revenue forecast ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2025. Novavax, Inc. (Nasdaq: NVAX) today announced that it will ...